Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vagal Control of Glucose Homeostasis in AAW
NCT02365285Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Mar 2015
- Primary completion
- Oct 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galantamine in obesity (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in Oxidative Stress: Baseline to 2 Hours and Change in Oxidative Stress: Baseline to 4 Hours. Started Mar 2015; status: completed.
02
Drugs
galantamine
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02365285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365285.